The Technical Analyst
Third Harmonic Bio, Inc. [THRD]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Third Harmonic Bio, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.45% $11.93
/ 7 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 486.23 mill |
| EPS: | -0.780 |
| P/E: | -15.29 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 40.76 mill |
| Avg Daily Volume: | 0.154 mill |
| RATING 2024-05-07 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -15.29 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -15.29 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$6.69 (-43.95%) $-5.24 |
| Date: 2024-05-07 |
| Expected Trading Range (DAY) |
|---|
|
$ 11.19 - 12.67 ( +/- 6.19%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Holles Natalie C. | Buy | 13 558 | Common Stock |
| 2024-04-11 | Holles Natalie C. | Sell | 13 558 | Common Stock |
| 2024-04-11 | Holles Natalie C. | Sell | 13 558 | Employee Stock Option (right to buy) |
| 2024-04-04 | Person Julie | Sell | 1 107 | Employee Option Grant (right to buy) |
| 2024-04-04 | Person Julie | Buy | 1 107 | Common Stock |
| INSIDER POWER |
|---|
| 5.79 |
| Last 98 transactions |
| Buy: 24 902 019 | Sell: 27 277 881 |
Forecast:
16:00 - $11.92
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $11.92
Forecast 2: 16:00 - $11.92
Forecast 3: 16:00 - $11.92
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $11.93 (1.45% ) |
| Volume | 0.0826 mill |
| Avg. Vol. | 0.154 mill |
| % of Avg. Vol | 53.58 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For THRD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:30 | buy | $9.05 | N/A | Active |
|---|
THRD
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-03-28 08:30:00 - Press Release
Third Harmonic Bio Appoints Geoff Mcdonough, M.d., To Its Board Of Directors
San francisco, march 28, 2024 (globe newswire) -- third harmonic bio, inc. (nasdaq: thrd), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of geoff mcdonough, m.d., to its board of directors.
2024-03-26 08:05:00 - Press Release
Third Harmonic Bio Announces Fourth Quarter And Full Year 2023 Financial Results
U.s. ind filed for thb335 with anticipated clinical trial start during 2q'24 strong financial position with cash and cash equivalents totaling $269.1 million as of december 31, 2023 san francisco, march 26, 2024 (globe newswire) -- third harmonic bio, inc. (nasdaq: thrd), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended december 31, 2023. “our team's execution continues to be outstanding, with the filing of our u.s. ind for thb335 ahead of our internal timelines for submission,” said natalie holles, chief executive officer of third harmonic bio.
2024-02-26 16:00:00 - Press Release
Third Harmonic Bio To Participate In The 44th Annual Td Cowen Health Care Conference
San francisco, feb. 26, 2024 (globe newswire) -- third harmonic bio, inc. (nasdaq: thrd), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that chief executive officer, natalie holles, will participate in a fireside chat at the 44th annual td cowen health care conference on tuesday, march 5, 2024, at 1:30 p.m. et.
2024-02-22 11:08:00 - Press Release
Shareholder Alert: Purcell & Lefkowitz Llp Announces Shareholder Investigation Of Third Harmonic Bio, Inc. (nasdaq: Thrd)
New york , feb. 22, 2024 /prnewswire/ -- purcell & lefkowitz llp announces that it is investigating third harmonic bio, inc. (nasdaq: thrd) on behalf of the company's shareholders. the investigation seeks to determine whether third harmonic bio's directors breached their fiduciary duties in connection with recent corporate actions.
2024-01-04 08:00:00 - Press Release
Third Harmonic Bio Appoints Christopher Murphy As Chief Financial And Business Officer And Provides Business Update
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy
Latest News
2023-12-29 13:32:16 - Zacks Investment Research
Are You Looking for a Top Momentum Pick? Why Third Harmonic Bio, Inc. (THRD) is a Great Choice
Does Third Harmonic Bio, Inc. (THRD) have what it takes to be a top stock pick for momentum investors? Let's find out.
2023-08-31 08:30:00 - GlobeNewsWire
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023, from 7:30-7:55 a.m. ET.
2023-02-03 13:35:21 - Benzinga
Top 5 Health Care Stocks That May Rally - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-01-10 07:33:59 - Benzinga
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2022-12-15 11:37:24 - InvestorPlace
Why Is Third Harmonic Bio (THRD) Stock Down 75% Today?
Long-term investors of Third Harmonic Bio (NASDAQ: THRD ) are feeling some discomfort today, to put it mildly. This morning, THRD stock is losing the majority of its value because the company halted a clinical trial.
2022-12-15 08:22:56 - Market Watch
Third Harmonic's stock falls 75% after discontinuing clinical trial
Shares of Third Harmonic Bio Inc. tumbled 75% in premarket trading on Thursday after the company said it discontinued the Phase 1b study of its treatment for chronic inducible urticaria, a common inflammatory skin condition, over safety concerns. Third Harmonic said it plans to provide the full data from the study as well as an update on its corporate strategy in early 2023.
2022-09-21 17:54:08 - GuruFocus
Third Harmonic Scores Most Successful Biotech IPO in Months
A partner in a large Cambridge, Massachusetts-based venture capital firm is confident that investors' appetite for biotech startups will begin to pick up in the fall.
2022-09-15 14:18:42 - InvestorPlace
Is Third Harmonic Bio (THRD) Stock the Next Red-Hot IPO?
One of the hottest recent biotech initial public offerings belongs to Third Harmonic (NASDAQ: THRD ). Today, this early stage biotech company focused on developing a drug for allergic and inflammatory diseases went public.
2022-09-15 11:41:22 - Market Watch
Third Harmonic Bio stock opens more than 20% above IPO price
Third Harmonic Bio Inc. THRD, +22.50% received a warm Wall Street welcome Thursday, as the biotechnology company's stock opened 20.6% above the initial public offering price. The company, which specializes in allergic and inflammatory diseases, said early Thursday that its IPO priced at $17 a share, in the middle of the expected range, as the company raised $185.3 million.